1.9000
06-一月-25 16:45:00
15 分钟延时
股票
+0.1500
+8.57%
今日范围
1.7500 - 2.5200
ISIN
N/A
来源
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 9月 2024 08:30:00 条件 Nasdaq GlobeNewswire